They tested Opdivo (Nivolumab) with either the standard dose of Avastin (Bevacizumab) or a lower dose of Avastin for recurrent Glioblastoma. The combinations really did not do that well, but they found that the lower dose of worked just as good as the standard dose. This is important because this is an expensive drug. If we could cut the dose we not only save money but possibly minimize side effects.
Some patients did benefit, but the median patient really did not. They need to figure out which patients benefit and why, as well as which patients would not benefit and why.